TITLE

Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda

AUTHOR(S)
Amuron, Barbara; Namara, Geoffrey; Birungi, Josephine; Nabiryo, Christine; Levin, Jonathan; Grosskurth, Heiner; Coutinho, Alex; Jaffar, Shabbar
PUB. DATE
January 2009
SOURCE
BMC Public Health;2009, Vol. 9, p290
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: In many HIV programmes in Africa, patients are assessed clinically and prepared for antiretroviral treatment over a period of 4-12 weeks. Mortality rates following initiation of ART are very high largely because patients present late with advanced disease. The rates of mortality and retention during the pre-treatment period are not well understood. We conducted an observational study to determine these rates. Methods: HIV-infected subjects presenting at The AIDS Support Clinic in Jinja, SE Uganda, were assessed for antiretroviral therapy (ART). Eligible subjects were given information and counselling in 3 visits done over 4-6 weeks in preparation for treatment. Those who did not complete screening were followed-up at home. Survival analysis was done using poisson regression. Results: 4321 HIV-infected subjects were screened of whom 2483 were eligible for ART on clinical or immunological grounds. Of these, 637 (26%) did not complete screening and did not start ART. Male sex and low CD4 count were associated independently with not completing screening. At follow-up at a median 351 days, 181 (28%) had died, 189 (30%) reported that they were on ART with a different provider, 158 (25%) were alive but said they were not on ART and 109 (17%) were lost to follow-up. Death rates (95% CI) per 100 person-years were 34 (22, 55) (n.18) within one month and 37 (29, 48) (n.33) within 3 months. 70/158 (44%) subjects seen at follow-up said they had not started ART because they could not afford transport. Conclusion: About a quarter of subjects eligible for ART did not complete screening and pretreatment mortality was very high even though patients in this setting were well informed. For many families, the high cost of transport is a major barrier preventing access to ART.
ACCESSION #
44171703

 

Related Articles

  • Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in C�te d'Ivoire. Ekouevi, Didier K.; Coffie, Patrick A.; Chaix, Marie-Laure; Tonwe-Gold, Besigin; Clarisse Amani-Bosse; Leroy, Val�riane; Abrams, Elaine J.; Dabis, Fran�ois // Journal of the International AIDS Society;2010, Vol. 13 Issue 1, p1 

    Background: Information is currently limited on the long-term follow up of HIV-1 infected women who are on highly active antiretroviral therapy (HAART) that contains nevirapine and lamivudine and who were previously exposed to antiretroviral drugs for the prevention of mother to child...

  • New study puts forth HIV treatment as prevention.  // HIV/AIDS Policy & Law Review;Oct2010, Vol. 15 Issue 1, p7 

    The article focuses on the study conduced by the BC Centre for Excellence in HIV/AIDS (BC-CfE), according to which the highly active antiretroviral therapy (HAART) extend far beyond treatment of HIV/AIDS. It shows that the expansion of HAART has proved to be an important prevention tool that can...

  • Differing indications. Seid, Cherinet // CMAJ: Canadian Medical Association Journal;9/1/2009, Vol. 181 Issue 5, pE85 

    The article discusses the developments in the treatment of people having HIV and AIDS in Ethiopia. It notes there are centres in Addis Ababa, the capital city, offering HIV care which includes highly-active antiretroviral treatment. According to the article, the establishment of highly-active...

  • Primary HIV Infection, Phylogenetics, and Antiretroviral Prevention. Pillay, Deenan; Fisher, Martin // Journal of Infectious Diseases;4/1/2007, Vol. 195 Issue 7, p924 

    The article discusses the highly active antiretroviral therapy (HAART) for HIV infection. HAART is the therapy, composed of multiple anti-HIV drugs prescribed to many HIV-positive people, even before they develop symptoms of AIDS. The therapy usually includes one nucleoside analog, or DNA chain...

  • Emerging of HIV Drug Resistance: Epidemiology, Diagnosis, Treatment and Prevention. Sasisopin Kiertiburanaku; Somnuek Sungkanuparph // Current HIV Research;May2009, Vol. 7 Issue 3, p273 

    Antiretroviral therapy for HIV/AIDS patients are used globally including in resource-limited settings. Successful outcomes are not always observed and HIV resistance to antiretroviral agents is a major cause of treatment failure. Both primary and secondary drug resistance have been described and...

  • HIV/AIDS.  // Africa Health;Sep2014, Vol. 36 Issue 6, p51 

    The article discusses the findings of research related to the prevention and treatment of AIDS and HIV infections. A randomized clinical trial conducted in Malawi shows that offering optional home initiation of HIV care increases the proportion of adults initiating antiretroviral therapy (ART)....

  • AIDS Conference: Encouraging Advances Amid Funding Worries for Global Treatment. Stephenson, Joan // JAMA: Journal of the American Medical Association;9/8/2010, Vol. 304 Issue 10, p1053 

    The article discusses the highlights of the XVIII International AIDS Conference (IAC) held in Vienna, Austria. The conference highlighted protests against the declining fund for antiretroviral therapy (ART) due to the global economic crisis. It also announced the new HIV treatment guideline,...

  • Integrating HIV/AIDS and Alcohol Research. BRYANT, KENDALL J.; NELSON, STEVE; BRAITHWAITE, R. SCOTT; ROACH, DEIDRA // Alcohol Research & Health;2010, Vol. 33 Issue 3, p167 

    Many people at risk for or already infected with HIV abuse alcohol, contributing to the difficulties in preventing the spread of the infection and treating infected patients. Thus, alcohol-abusing patients may delay testing for HIV, accessing appropriate medical care, and initiating...

  • CAN SAN FRANCISCO BECOME AMERICA'S FIRST AIDS-FREE CITY? Lybarger, Jeremy // Advocate;Apr/May2014, Issue 1072, p46 

    The article discusses how San Francisco, California is striving to become AIDS-free, following its reputation as the AIDS epicenter of the world. Topics include its commitment to being the first city to reach zero new HIV transmissions and zero AIDS patients, comments from HIV/AIDS researcher...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics